Related Experiment Video
Updated: Jul 21, 2025

Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
Characterization of cytoskeletal and structural effects of INF2 variants causing glomerulopathy and neuropathy
Hiroko Ueda1, Quynh Thuy Huong Tran1, Linh Nguyen Truc Tran1
1Division of Nephrology, Second Department of Internal Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1191, Japan.
Abstract:
Focal segmental glomerulosclerosis (FSGS) is a common glomerular injury leading to end-stage renal disease. Monogenic FSGS is primarily ascribed to decreased podocyte integrity. Variants between residues 184 and 245 of INF2, an actin assembly factor, produce the monogenic FSGS phenotype. Meanwhile, variants between residues 57 and 184 cause a dual-faceted disease involving peripheral neurons and podocytes (Charcot-Marie-Tooth CMT/FSGS). To understand the molecular basis for INF2 disorders, we compared structural and cytoskeletal effects of INF2 variants classified into two subgroups: One (G73D, V108D) causes the CMT/FSGS phenotype, and the other (T161N, N202S) produces monogenic FSGS. Molecular dynamics analysis revealed that all INF2 variants show distinct flexibility compared to the wild-type INF2 and could affect stability of an intramolecular interaction between their N- and C-terminal segments. Immunocytochemistry of cells expressing INF2 variants showed fewer actin stress fibers, and disorganization of cytoplasmic microtubule arrays. Notably, CMT/FSGS variants caused more prominent changes in mitochondrial distribution and fragmentation than FSGS variants and these changes correlated with the severity of cytoskeletal disruption. Our results indicate that CMT/FSGS variants are associated with more severe global cellular defects caused by disrupted cytoskeleton-organelle interactions than are FSGS variants. Further study is needed to clarify tissue-specific pathways and/or cellular functions implicated in FSGS and CMT phenotypes.
Insights
INF2 gene variants cause kidney disease (FSGS) and nerve disorders (CMT/FSGS). CMT/FSGS variants disrupt cell structures more severely than FSGS variants, impacting mitochondria and cellular integrity.
Area of Science:
- Nephrology
- Genetics
- Cell Biology
Background:
- Focal segmental glomerulosclerosis (FSGS) is a major cause of end-stage renal disease, often linked to podocyte dysfunction.
- Monogenic FSGS arises from genetic defects, particularly in the INF2 gene, which affects actin dynamics.
- INF2 variants can lead to isolated FSGS or a combined Charcot-Marie-Tooth disease and FSGS (CMT/FSGS) phenotype.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying INF2-related disorders by comparing FSGS and CMT/FSGS variants.
- To investigate the structural and cytoskeletal consequences of specific INF2 variants.
Main Methods:
- Molecular dynamics simulations were used to analyze the flexibility and stability of wild-type and variant INF2 proteins.
- Immunocytochemistry was employed to assess cytoskeletal organization (actin stress fibers, microtubules) and mitochondrial morphology in cells expressing INF2 variants.
Main Results:
- All analyzed INF2 variants exhibited altered flexibility compared to wild-type, potentially affecting intramolecular interactions.
- INF2 variants led to reduced actin stress fibers and disorganized microtubule arrays.
- CMT/FSGS variants induced more significant mitochondrial fragmentation and altered distribution than FSGS variants, correlating with cytoskeletal disruption severity.
Conclusions:
- INF2 variants associated with CMT/FSGS cause more profound cellular defects, including disrupted cytoskeleton-organelle interactions, compared to FSGS-only variants.
- The findings highlight distinct cellular impacts of INF2 variants, suggesting different pathogenic pathways for FSGS and CMT/FSGS.
- Further research is required to understand tissue-specific mechanisms and cellular functions involved in these complex disorders.
Related Concept Videos
Types of Intermediate Filaments
Nephrotic Syndrome I : Introduction

